An increase in the proportion of serum IgA molecules that are poorly O-galactosylated has been one of the most consistent findings in studies of IgAN over the past decade. 1,2 Perhaps more ...

In a phase 2 study, iptacopan — an oral, highly potent proximal complement inhibitor — reduced proteinuria in patients with IgA nephropathy. New research findings from a phase 3 trial are ...

"Mounting clinical evidence underscores the pivotal role of complement activation in IgA nephropathy," she added. "I am thrilled that this advancement is now available to help enable a targeted ...

The FDA has given breakthrough therapy designation to OMS721, a new treatment for the rare kidney disease immunoglobulin A (IgA ... target involved in activation of the complement system, an ...

a small molecule inhibitor designed to treat glomerular diseases with abnormal complement activation, such as IgA nephropathy. This development underscores the company’s commitment to advancing ...